Physician profile
Michael Eugene Herrmann
NPI 1164525093
$4,422.58
in general payments reported to CMS, 2019-2025
23 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $883 · 2020: $388 · 2021: $1,003 · 2022: $881 · 2023: $722 · 2024: $274 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,218 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,218.00 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,570.32 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $696.55 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $332.11 | 2019-2021 | |
| Organon LLC | $223.09 | 2021-2025 | Nexplanon |
| Agile Therapeutics, INC. | $199.37 | 2021-2024 | Twirla |
| Myovant Sciences INC. | $186.13 | 2021-2022 | |
| Exeltis, USA INC. | $174.85 | 2019-2025 | Slynd |
| Supernus Pharmaceuticals, INC. | $145.01 | 2022-2023 | Qelbree |
| Allergan, INC. | $126.58 | 2019-2020 | |
| Astellas Pharma US INC | $114.13 | 2023-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $103.89 | 2023-2025 | Myfembree |
| Avion Pharmaceuticals | $85.51 | 2020-2022 | |
| Lupin INC. | $59.24 | 2020-2021 | |
| Hologic Sales and Service, LLC | $54.81 | 2022-2024 | Thinprep 2000 Processor, Aptima, Third Wave |
| Mylan Pharmaceuticals INC. | $52.13 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $50.00 | 2023 | Nexletol |
| Pfizer INC. | $49.08 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.31 | 2019-2023 | |
| Novo Nordisk INC | $45.22 | 2021 | |
| Therapeuticsmd, INC. | $45.09 | 2019-2022 | |
| Daiichi Sankyo INC. | $28.46 | 2022 | |
| Exact Sciences Corporation | $19.08 | 2025 | The Cologuard Plus Collection Kit |
| Millicent US INC | $14.62 | 2025 | Femlyv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Herrmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.